276 related articles for article (PubMed ID: 35868481)
1. Inhaled therapy for COVID-19: Considerations of drugs, formulations and devices.
Saha T; Quiñones-Mateu ME; Das SC
Int J Pharm; 2022 Aug; 624():122042. PubMed ID: 35868481
[TBL] [Abstract][Full Text] [Related]
2. Antivirals and the Potential Benefits of Orally Inhaled Drug Administration in COVID-19 Treatment.
Sahin G; Akbal-Dagistan O; Culha M; Erturk A; Basarir NS; Sancar S; Yildiz-Pekoz A
J Pharm Sci; 2022 Oct; 111(10):2652-2661. PubMed ID: 35691607
[TBL] [Abstract][Full Text] [Related]
3. Repurpose but also (nano)-reformulate! The potential role of nanomedicine in the battle against SARS-CoV2.
Tammam SN; El Safy S; Ramadan S; Arjune S; Krakor E; Mathur S
J Control Release; 2021 Sep; 337():258-284. PubMed ID: 34293319
[TBL] [Abstract][Full Text] [Related]
4. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
5. Treatment of respiratory viral infections through inhalation therapeutics: Challenges and opportunities.
Nainwal N
Pulm Pharmacol Ther; 2022 Dec; 77():102170. PubMed ID: 36240985
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic drugs for SARS-CoV-2 treatment: Current state and perspective.
Bolarin JA; Oluwatoyosi MA; Orege JI; Ayeni EA; Ibrahim YA; Adeyemi SB; Tiamiyu BB; Gbadegesin LA; Akinyemi TO; Odoh CK; Umeobi HI; Adeoye AB
Int Immunopharmacol; 2021 Jan; 90():107228. PubMed ID: 33302035
[TBL] [Abstract][Full Text] [Related]
7. Molecular Insights of SARS-CoV-2 Infection and Molecular Treatments.
Abdurrahman L; Fang X; Zhang Y
Curr Mol Med; 2022; 22(7):621-639. PubMed ID: 34645374
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of repurposed antiviral drugs: Lessons from COVID-19.
Martinez MA
Drug Discov Today; 2022 Jul; 27(7):1954-1960. PubMed ID: 35192924
[TBL] [Abstract][Full Text] [Related]
9. Drugs repurposing for SARS-CoV-2: new insight of COVID-19 druggability.
Debnath SK; Debnath M; Srivastava R; Omri A
Expert Rev Anti Infect Ther; 2022 Sep; 20(9):1187-1204. PubMed ID: 35615888
[TBL] [Abstract][Full Text] [Related]
10. Formulation, Device, and Clinical Factors Influencing the Targeted Delivery of COVID-19 Vaccines to the Lungs.
Mossadeq S; Shah R; Shah V; Bagul M
AAPS PharmSciTech; 2022 Nov; 24(1):2. PubMed ID: 36416999
[TBL] [Abstract][Full Text] [Related]
11. COVID-19: Underpinning Research for Detection, Therapeutics, and Vaccines Development.
Aljabali AAA; Bakshi HA; Satija S; Metha M; Prasher P; Ennab RM; Chellappan DK; Gupta G; Negi P; Goyal R; Sharma A; Mishra V; Dureja H; Dua K; Tambuwala MM
Pharm Nanotechnol; 2020; 8(4):323-353. PubMed ID: 32811406
[TBL] [Abstract][Full Text] [Related]
12. Investigational antiviral drugs for the treatment of COVID-19 patients.
Beheshtirouy S; Khani E; Khiali S; Entezari-Maleki T
Arch Virol; 2022 Mar; 167(3):751-805. PubMed ID: 35138438
[TBL] [Abstract][Full Text] [Related]
13. Can Resveratrol-Inhaled Formulations Be Considered Potential Adjunct Treatments for COVID-19?
Rossi GA; Sacco O; Capizzi A; Mastromarino P
Front Immunol; 2021; 12():670955. PubMed ID: 34093569
[TBL] [Abstract][Full Text] [Related]
14. Current Therapeutics for COVID-19, What We Know about the Molecular Mechanism and Efficacy of Treatments for This Novel Virus.
Narayanan D; Parimon T
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887042
[TBL] [Abstract][Full Text] [Related]
15. Inhaled route and anti-inflammatory action of ivermectin: Do they hold promise in fighting against COVID-19?
Mittal N; Mittal R
Med Hypotheses; 2021 Jan; 146():110364. PubMed ID: 33246694
[TBL] [Abstract][Full Text] [Related]
16. Progress, pitfalls, and path forward of drug repurposing for COVID-19 treatment.
Taibe NS; Kord MA; Badawy MA; Shytaj IL; Elhefnawi MM
Ther Adv Respir Dis; 2022; 16():17534666221132736. PubMed ID: 36282077
[TBL] [Abstract][Full Text] [Related]
17. Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research.
Bimonte S; Crispo A; Amore A; Celentano E; Cuomo A; Cascella M
In Vivo; 2020 Jun; 34(3 Suppl):1597-1602. PubMed ID: 32503817
[TBL] [Abstract][Full Text] [Related]
18. Pathogenesis-directed therapy of 2019 novel coronavirus disease.
Stratton CW; Tang YW; Lu H
J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355
[TBL] [Abstract][Full Text] [Related]
19. An overview of potential therapeutic agents to treat COVID-19.
Dong X; Tian Z; Shen C; Zhao C
Biosci Trends; 2020 Nov; 14(5):318-327. PubMed ID: 33100290
[TBL] [Abstract][Full Text] [Related]
20. TMPRSS2 and RNA-Dependent RNA Polymerase Are Effective Targets of Therapeutic Intervention for Treatment of COVID-19 Caused by SARS-CoV-2 Variants (B.1.1.7 and B.1.351).
Lee J; Lee J; Kim HJ; Ko M; Jee Y; Kim S
Microbiol Spectr; 2021 Sep; 9(1):e0047221. PubMed ID: 34378968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
